HT-100 Long-term Study in DMD Patients Who Completed HALO-DMD-02

Summary

This study, HALO-DMD-03, is a follow-on study to HALO-DMD-01 and HALO-DMD-02, and allows continued open-label access to HT-100 for subjects who have completed these studies. HALO-DMD-03 will provide safety and strength and function data on continuous long-term dosing. Data from this study will be used to inform the safety, tolerability, and dose selection for a future trial of HT-100 in boys with Duchenne Muscular Dystrophy (DMD).

Timeline

Start

2015-05

Primary completion

2016-12-30

Completion

2016-12-30

Outcome

Outcome not reported

Stopped: “Dosing stopped”

Drugs

Indications